



BRIAN D. JELLISON
CANCER
INSTITUTE

2021

CANCER ANNUAL REPORT
SARASOTA MEMORIAL HEALTH CARE SYSTEM

SARASOTA
MEMORIAL
BRIAN D. JELLISON
CANCER INSTITUTE

An exceptionally rewarding and challenging year

The year 2021 has been both an exceptionally rewarding and challenging year for the Brian D. Jellison Cancer Institute (Jellison Cancer Institute) at Sarasota Memorial Health Care System, as we continued to expand our services and facilities while delivering high-quality patient care to our community during the COVID-19 Pandemic.

The Jellison Cancer Institute team has adapted to the current environment to continue to meet the needs of cancer patients. They have maintained a patient-centered and safe environment for patients and their families. Through our physicians, nurses, nurse navigators, and other oncology staff, patients are able to receive the full continuum of cancer care within the Sarasota Memorial Health Care System.

Our services continued to expand this year. The Oncology Tower at SMH - Sarasota opened for patient care in November 2021. The 8-story Tower includes surgical services, inpatient services, oncology supportive care services, and a Rooftop Café. We are thrilled that our staff and patients have a dedicated environment to provide and receive cancer care close to home.

As we grew our physical footprint in 2021, we were also able to expand our Tumor Board conferences. The multidisciplinary conferences allow patient cases to be reviewed by a team of expert clinicians to determine the most advantageous treatment plan for patients. The Jellison Cancer Institute increased their offerings to seven tumor-site specific conferences, averaging five active conferences per week. We strongly believe this is providing patients with individualized, high-quality care.

The Oncology Thrive Program continued to operate remotely, offering oncology patients a safer option of wellness and support classes. Ensuring patients receive the necessary supportive care post-treatment, we launched the specialized Survivorship program, providing access to free nutrition, education and psychosocial support. In addition, in 2021 we promoted multiple clinical trials and new innovative technology, and continued recruiting specialized oncology physicians.

We are proud of what the Jellison Cancer Institute team accomplished despite the unique challenges of this year. We are excited for 2022 and all the success that the year will bring to the Jellison Cancer Institute.

Sincerely,

A handwritten signature in black ink that reads "Richard H. Brown".

Dr. Richard Brown
Medical Director,
Brian D. Jellison Cancer Institute

A handwritten signature in black ink that reads "Kelly Batista".

Kelly Batista
Executive Director,
Brian D. Jellison Cancer Institute

Program Statistics

Sarasota Memorial Hospital (SMH) cancer registry is responsible for data collection of cancer cases diagnosed and/or treated within the SMH healthcare system. A complete summary of the history, diagnosis, treatment and disease status for each cancer case is input into a database using standardized codes by our Certified Tumor Registrars. Analysis of the data within the cancer registry allows cancer program professionals to monitor trends in cancer incidence, prevalence, survival and mortality.

In 2020, breast, lung, prostate, bladder and colon were the top five new cancers sites diagnosed and/or treated at SMH, and they comprised over 60% of all new cases. Data from the SMH cancer registry is also shared with the Florida Cancer Data System (FCDS) and the National Cancer Database (NCDB) annually for use by epidemiologists, researchers, legislators, physicians and public health professionals.

Multidisciplinary Conferences Held (2021)	Total
Breast	49
Gastrointestinal	50
General/Lung	49
Genitourinary/GYN	24
Neuro	72
Thyroid	3


Top Tumor Sites	Total (Analytic Cases)	Male	Female
Colon	113	59	54
Lung	352	169	183
Breast	442	2	440
Uterus	60	-	60
Prostate	441	441	-
Urinary Bladder	137	107	30
All Cancers (2020)	2,471	1,285	1,186

Case Presented (2021)	Total
Breast	362
Gastrointestinal	570
General/Lung	258
Genitourinary/GYN	235
Neuro	78
Thyroid	12

Service

In Summer 2021, the Brian D. Jellison Cancer Institute Radiation Oncology Center at University Parkway implemented Surface Guided Radiation Therapy (SGRT), an advanced technology to ensure accurate treatment delivery for cancer patients. When cancer patients receive radiation therapy, the treatment can be extremely close to other critical organs. SGRT provides a new level of precision, ensuring the radiation beam is specific, accurate and minimizes any future health concerns.

The new technology, Align RT, uses 3-D cameras to capture the patient's exact position during simulation and treatment. As the patient progresses through treatment, Align RT can detect any amount of movement from the patient and automatically pause the radiation beam until the patient is realigned for the best treatment outcome. This allows for radiation therapy to only be given in the exact location necessary.



"SGRT provides an important safeguard. Treatment is only initiated once the surface guidance system assures optimal patient positioning. By providing continuous monitoring during radiation therapy, treatment is immediately halted if the patient is to move out of the appropriate position as per the customized radiation treatment plan for that patient", says Radiation Oncologist, Dr. Kunal Saigal. "SGRT improves the quality of radiation therapy delivery to every anatomical location on the body. It should be considered a gold-standard for modern radiation therapy delivery. We are excited to offer this level of care to our community".

In 2022, the Jellison Cancer Institute will utilize another benefit of Align RT, eliminating the need for tattoos or other permanent markers on patients' skin and moving to a 'mark less' treatment for all cancer types.

Community Outreach

The Sarasota Memorial Brian D. Jellison Cancer Institute is committed to serving our community. Our Cancer Institute staff dedicates their time to provide education on cancer prevention, accessible screenings, and survivorship support. Although 2021 was still impacted by the Pandemic, our team was able to participate in events throughout the community.



The Brian D. Jellison Cancer Institute team participated in the American Cancer Society Making Strides Against Breast Cancer Walk on Saturday, October 16, 2021.



The Brian D. Jellison Cancer Institute participated in Breast Fest on Saturday, December 18, 2021. The event was hosted by the Sarasota Department of Health, and utilized a mobile mammography unit to provide 3D mammography screenings to underserved populations in the community.

Antonio Gonzalez Martin, RN (Health Dept.), Veronica Martinez, MSN (SMH), Jenny Brown, BSN (SMH), Candy Leckey RN (Health Dept.), William Freitas (Health Dept.), Jan Chulock, RN (Health Dept.), Rachelle Jackson (SMH), Deena Dell, APRN (SMH), and Yulonda Green (SMH)



Veronica Martinez, MSN, Jenny Brown, BSN, Deena Dell, APRN

Virtual Cervical Cancer Talk

In June, the Jellison Cancer Institute hosted a virtual cervical cancer education event. Dr. Beverly Long, gynecologic oncology surgeon, provided information on prevention and screening for cervical cancer. Dr. Long is dedicated to the care of women with gynecologic malignancies and complex surgical needs, with a focus on complex ovarian cancer surgery, fertility-sparing and risk-reducing surgeries, robotic and minimally invasive surgeries, and biopsies and screenings. Dr. Long shared an in-depth presentation on cervical cancer and the importance of prevention through the HPV vaccine, and answered any questions the community had on the topic.

Spotlight:

Scarless Transoral Thyroidectomy

In July 2021, Dr. Ralph Tufano joined First Physicians Group as Medical Director of Head and Neck Endocrine Surgery at Sarasota Memorial. Dr. Tufano is a Board Certified Otolaryngologist, specializing in thyroid and parathyroid surgery. Traditional thyroidectomies and parathyroidectomies leave a visible scar at the thyroid, in the middle of the neck region. Dr. Tufano uses an innovative, scarless approach for improved patient outcomes. This recent advancement in surgical capabilities, brings a new alternative for patients with no external skin incisions.

In the new approach, Dr. Tufano performs the surgery endoscopically by making three small incisions inside the bottom lip. He uses specialized instruments and technology to access the thyroid from this point, and removes any concerning tissue. Most patients are able to recover through our perioperative services within the same day, and are discharged to home with little discomfort. Patients have seen minimal to no external scarring from this procedure. There are only a small number of surgeons around the world able to perform this surgery.

Dr. Tufano is also building the foundation for a future expansion of a dedicated Head and Neck oncology program at Sarasota Memorial. We are fortunate to have Dr. Tufano's expertise in our community, and ability to offer such an advanced technique to our cancer patients.



“Our goal is to be as conservative as possible and provide the best outcomes with the most effective and personalized approach available.”

Ralph P. Tufano, MD, MBA
*Medical Director of Head
and Neck Endocrine Surgery
Thyroid and Parathyroid Center*

Nursing

The Brian D. Jellison Cancer Institute is home to many dedicated nurses who have a passion for oncology as a specialty. Sarasota Memorial values and supports nursing certification to ensure the highest quality of care for our patients. Being a Magnet nursing organization allows us greater opportunity to recruit skilled nurses and expand specialized services with these qualified professionals.

The preparation to open and transition into the new Oncology Tower was well under way throughout 2021. For the inpatient oncology nursing units, this required significant onboarding of nurses to staff the expanded inpatient capacity and specialization division. Oncology Leadership sourced a variety of new graduate nurses, experienced medical/surgical nurses, and experienced oncology nurses from the region and beyond. It was evident that training for a large number of nurses would require dedicated, structured education. Thus, Oncology Nursing created the Oncology Residency Program.

The Program was specifically tailored to the needs of the individual nurses who were brought onto the team. The Oncology Residency Program consists of oncology nursing specific education to adequately prepare nurses to care for complex oncology patients. The Program works in conjunction with the hospital's current Nurse Residency Program for new graduate nurses, and streamlines education for all nurses coming to the inpatient oncology units. The education provided includes the Cancer Basics Course, as well as the Fundamentals of Chemotherapy Immunotherapy Administration, which are both provided in collaboration with the Oncology Nursing Society. This education is followed by interactive practical skills training highlighting safe chemotherapy administration, other clinical protocols, and expectations in our organization. Once eligible, nurses were provided additional education and support in obtaining their advanced Oncology Nursing Certification.



Oncology Nursing
Certification

Research

SMH Cancer Research & Clinical Trials

The SMH Cancer Research Program focuses on innovation, prevention, and treatment with the goal of advancing the practice of medicine and improving the quality of care for patients in our community.

Gynecologic Trials

Beverly Long, MD, a Principal Investigator opened several new GYN protocols in 2021.

- A new surgical NRG collaborative trial through the National Cancer Institute (NCI) for comparison of non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancers among BRCA1 carriers.
- A treatment NRG Collaborative trial through NCI for endometrial cancer for measurable stage 3 or 4b, or recurrent disease.
- Partnering with George Washington University, Dr Long initiated the SELFIE trial, a grant funded trial that assesses novel markers for cervical cancer screening from self-collected samples.
- Several other pharmaceutical sponsored studies are available for GYN cancer patients including a new drug study for recurrent or persistent uterine serous carcinoma, platinum-resistant recurrent ovarian cancer, and advanced or recurrent endometrial cancer drug trial with patients with mismatch repair deficient (dMMR) in the first-line setting.



COVID-19 Cancer Trials

James Fiorica, MD, is the Principal Investigator of the NCI COVID-19 in Cancer Patients Study: A Longitudinal Natural History Study. This will provide information on the long-term effects of COVID on cancer patients.



Gastrointestinal/Pancreatic Trials

Kenneth Meredith, MD, is a Principal Investigator of GI/Pancreatic Cancer research, and is actively engaged in an innovative trial with targeted treatment for advanced pancreatic cancer. This study is a successful collaboration between Dr. Meredith and Dr. Lee, interventional radiologist. In addition, Dr. Meredith collaborates with local medical oncologists on a new pharmaceutical sponsored trial for the treatment of advanced pancreatic cancer that is un-resectable or recurrent.



Lung Trials

Joseph Seaman, MD, Principal Investigator of Lung Cancer research is actively engaged in several research studies.

- An observational study to evaluate the development of a molecular test for early diagnosis of lung cancer from a blood sample that is more sensitive and specific compared to existing tests.
- A study evaluating the use of the new Monarch Platform for robotic endoscopic bronchoscopy access and biopsy pulmonary lesions.
- An observational study to evaluate the performance of a blood test compared to an invasive procedure for low to moderate risk of cancer in patients with lung nodules.



Phase 1 Clinical Trial Collaboration

Over the last year, SMH has successfully collaborated with Florida Cancer Specialists' physicians, Dr. Manish Patel and Dr. Judy Wang, in the coordination and site of care support for Phase 1 Cancer Trials. Phase 1 Cancer Trials are essential, yet challenging, to coordinate due to the nature and length of observation required to safely monitor patients as safe drug dose is investigated. Through the collaboration with Florida Cancer Specialists, research patients are able to safely be treated by community physicians with smooth transition between outpatient and inpatient care needs related to innovative cancer drug trials.

Some of these Phase 1 trials include:

- A two-step clinical study in patients with advanced solid tumors with an escalating phase (Step 1) followed by an expansion phase (Step 2)
- An open-label study of TNB-585, a Bispecific Antibody Targeting PSMA in Subjects with Metastatic Castrate-Resistant Prostate Carcinoma
- An open-label study of a drug called SNX281 given as Monotherapy and in Combination with a Checkpoint Inhibitor in Subjects with Advanced Solid Tumors and Lymphoma
- An open- Label, multi-center, Phase 1/2 dose escalation and expansion study of THOR-707 as a single agent and in combination with pembrolizumab in adult subjects with advanced metastatic solid tumors



Interventional Oncology Trials

Justin Lee, MD, is the Principal Investigator for a nation-wide research initiative that assesses the safety, tolerability, and outcomes of the SIR-Spheres Y-90 treatment in patients with liver cancer. He will be opening the extension of this trial to assess the effectiveness of SIRT using SIR-Spheres Y-90 microspheres as first-line treatment for local control of Hepatocellular Carcinoma in 2022.



Scott Perrin, MD, is the Principal Investigator of a registry trial to develop parameter guidance for microwave liver ablation of soft tissue lesions.

Biorepository Trials

SMH research participates in several national biorepository partnerships in order to provide the scientific community with tissue and blood samples which may lead to new targeted therapies and screening diagnostics. Principal investigators for many of these biorepository studies are represented by doctors James Fiorica, Joseph Seaman, Kenneth Meredith, Robert Carey, and Russell Novak. SMH has become a networking partner of the Specimen Acquisition Network, consisting of eight health partners collaborating on best practices, enhancing access to high quality human specimens and data to drive innovative life sciences research.

Oncology Tower Opening



On November 15, 2021, the 180,000-square-foot, 8-story Oncology Tower on the SMH-Sarasota campus opened for patient care. As the cornerstone of the Brian D. Jellison Cancer Institute the Oncology Tower was designed around creating a patient-centered environment.

**SARASOTA
MEMORIAL**

BRIAN D. JELLISON
CANCER INSTITUTE

smh.com/cancer

Patient-Centered Environment

Operating Rooms

The Oncology Tower includes 9 state-of-the-art operating rooms, with 2 da Vinci Surgical Robots. Each room is constructed with stainless steel walls and the Clean Suite System for optimal cleanliness and efficiencies.




Post Anesthesia Care Unit

The Oncology Tower Post Anesthesia Care Unit (PACU) has 14 bays for patients to recover immediately after surgery. The Oncology Tower also includes 22 pre-operative/post-operative private rooms for patients to prepare for surgery, or continue to recovery after their surgery and time in PACU.

Private Inpatient Rooms

The Oncology Tower includes two patient floors with 56 total private patient rooms. The rooms were designed using a calming, patient-centered approach.



Rooftop Café

The Oncology Tower offers a unique dining option at the Rooftop Café for patients, visitors and staff. The Café is open for breakfast and lunch (7am - 4pm), providing fresh, whole food meal options, baked goods, and a smoothie and coffee bar.